Post-diagnostic Dietary Changes Among Men with Prostate Cancer Beneficial
the Cancer Therapy Advisor take:
General advice about diet from a qualified health professional may provide men diagnosed with prostate cancer with a focus for action and a means of trying to regain control, according to an article published online in the journal European Journal of Cancer Care.
In this study, eight men from the UK diagnosed with prostate cancer within the last 5 years reported changes they made to their diet post-diagnosis.
Two major themes were observed from the thematic analysis of the data: the first was about the perceived nature and importance of dietary change and the second about the perceived determinants of dietary change. The second theme focused on internal dimensions (eg agency) and external dimensions (eg, perceived role of relationship with health professionals, availability of dietary information with credibility, and family influences).
Furthermore, results showed family influences and context were linked to enabling men into implementing dietary changes.
General advice about diet from a qualified health professional may provide men diagnosed with prostate cancer with a focus for action.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed